Delivery Order SPE2DB22D1202-SPE2DB25FVHE1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,431.13 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency awarded a $6,125.92 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on September 15, 2025, with completion targeted for September 16, 2025. This non-competitive delivery order utilizes a firm fixed price structure and represents a small-value pharmaceutical supply transaction. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with a contract value of $20,902.70. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $30,324.00 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on September 16, 2025, with an ultimate completion date of September 17, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a child contract issued under a larger...
- The Defense Logistics Agency awarded a $40,673.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pens on September 5, 2025, with an ultimate completion date of September 8, 2025. This non-competitive, non-set-aside delivery order was issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $18,697.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on June 27, 2025, with a completion date of June 30, 2025. This competitive award uses firm fixed pricing and carries no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a child...
- The Defense Logistics Agency awarded a $13,120.39 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pens with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,037.49 delivery order on September 2, 2025, for Zepbound 10 mg/0.5 ml pen (semaglutide injection), with performance completion scheduled for September 3, 2025. The contract is structured as a firm fixed price delivery order under a non-competitive set-aside designation, with performance to be executed at the contractor's Conshohocken, Pennsylvania location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,537.40 on June 2, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of June 3, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHE1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $49,053.89 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, leverages its comprehensive IDC with the Defense Logistics Agency to supply a broad portfolio of pharmaceutical products and medical supplies to military and veteran healthcare systems. This delivery order for Zepbound, a diabetes and weight management medication, exemplifies the company's role as a critical vendor for federal medical procurement across multiple therapeutic domains. The underlying IDC serves as a global pharmaceutical support vehicle enabling the company to fulfill medical supply needs for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with flexible firm fixed-price delivery orders ranging significantly in value.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.1k | 8/12/25 |